Preview Mode Links will not work in preview mode
Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show offers a glimpse into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the evolving dynamics in the medical and healthcare landscape. One focus is on how providers, pharmaceutical companies, and payers are empowering patients.  In addition, conversations often focus on how technology is empowering providers, care facilities, pharmaceutical companies, and payers to improve patient outcomes and reduce friction across the healthcare landscape.  Popular Topics Include: Virtual and digital health Use of AI, ML, and robots for clinical and administrative purposes  Value-based healthcare  Precision and stratified medicine Next-generation immuno, cell, and gene therapies Vaccines for infectious diseases and oncology Biomarkers and diagnostics Rare diseases MedTech and medical devices Clinical trials  Population health Chronic conditions l Clinician and staff burnout Smart hospitals The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.

Nov 28, 2022

Dr. Tomasz George, Chief Scientific Officer of Virax Biolabs, has developed a novel test process that assesses adaptive immune responses to viruses. This information can inform decisions by patients and doctors on how to most effectively produce an immune response and boost personal protection from the next virus outbreak. An app delivers data about how an individual might respond to a virus and sends notices of specific viruses in a geographic location, along with links to diet and lifestyle suggestions.

Tomasz explains, "We also distribute and sell other viral testing products that look at viruses at different stages of infection and also your immunity at different stages. We intend to provide a subscription service in the next few months that actually allows you to test for these viruses on an ongoing basis, depending on which new viruses are at the moment. And this allows you to determine whether you would expect to cope with these viruses or not if you came in contact with them."

"We have a number of different avenues for selling our tests. We sell direct to consumers because it's a very informative test for people in general population groups. We also are looking to sell to governments, healthcare organizations, and pharma groups who will use our tests in different ways for population health management and management of governmental strategies. And also, for healthcare groups to identify patients who are most at risk and for pharma groups who can help to optimize the population that they study for things like drugs and vaccines by identifying patients who might respond better or worse to specific viruses."

@ViraxBiolabs #ViraxBiolabs #VRAX #ViraxCare #InfectiousDiseases #HealthTech #MedTech #BioTech #RealTimePCRDetection #RTPCR #PCRTest #AntibodyTest #BiomarkerTesting #COVID19

ViraxBiolabs.com

Download the transcript here

Virax